MedPath

Is Real-time CGM Superior to Flash Glucose Monitoring

Not Applicable
Conditions
Diabetes Mellitus, Type 1
Interventions
Device: Continuous Glucose Monitoring Guardian Connect Mobile system (real-time continuous glucose monitoring)
Device: Continuous Glucose Monitoring FreeStyle Libre Flash system (intermittently-scanned continuous glucose monitoring)
Registration Number
NCT04358263
Lead Sponsor
Charles University, Czech Republic
Brief Summary

The aim of the investigator's study is to compare real-time continuous glucose monitoring and flash glucose monitoring in adult patients with Type 1 Diabetes during 4-day training program focused on physical activity and over 4 weeks of follow-up.

Detailed Description

Not available

Recruitment & Eligibility

Status
UNKNOWN
Sex
All
Target Recruitment
60
Inclusion Criteria
  • patients with T1D naive to rtCGM and isCGM
  • Type 1 diabetes for >2 years
  • ≥ 18 years old
  • CSII or MDI
  • GOLD score < 4, no history of severe hypoglycemia within last 6 month
  • written informed consent prior to starting study related activity
Exclusion Criteria
  • severe noncompliance
  • severe diabetic retinopathy and/or macular edema
  • lactation, pregnancy, intending to become pregnant during study
  • condition likely to require MRI
  • use of acetaminophen-containing medication
  • unwillingness to use the study device for >70% of time

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
rtCGMContinuous Glucose Monitoring Guardian Connect Mobile system (real-time continuous glucose monitoring)Patients with use of the Guardian Connect Mobile system (real-time continuous glucose monitoring).
isCGMContinuous Glucose Monitoring FreeStyle Libre Flash system (intermittently-scanned continuous glucose monitoring)Patients with use of the FreeStyle Libre Flash system (intermittently-scanned continuous glucose monitoring).
Primary Outcome Measures
NameTimeMethod
Percentage of time in hypoglycemic rangesUp to 2 months

\<3,9 mmol/L (70 mg/dl) and \<3,0 mmol/L (54 mg/dl)

Secondary Outcome Measures
NameTimeMethod
Changes in glycemic variabilityUp to 2 months

Expressed as the coefficient of variation

Percentage of time in hyperglycemic rangesUp to 2 months

(\>10,0 mmol/L (180 mg/dl) and \>13,9 mmol/L (250 mg/dl)

Mean sensor glucose concentrationUp to 2 months

Measured by rtCGM or isCGM

Changes in glycated haemoglobin (HbA1c)Up to 2 months

Differences between HbA1c values in the initial period and after follow-up and differences of HbA1c between groups.

Percentage of time in target rangesUp to 2 months

3,9-10,0 mmol/L (70-180 mg/dl)

Changes in quality of life as assessed by validated questionnaireUp to 2 months

Assessed by The World Health Organization Quality of Life (WHOQOL)-BREF (Field Trial Version).

This questionnaire contains in total 26 questions in four Domains (Physical health, Psychological health, Social relationships, Environment). Scores in total range between 4-20 (each Domain 0-5), higher scores denote higher quality of life.

Incidence of severe hypoglycaemiaUp to 2 months

Requiring third-party assistance to treat

Trial Locations

Locations (1)

3rd Department of Internal Medicine, 1st Faculty of Medicine Charles University

🇨🇿

Prague, Czech Republic, Czechia

© Copyright 2025. All Rights Reserved by MedPath